Altered B cell homeostasis and toll-like receptor 9- driven response in type 1 diabetes carriers of the C1858T PTPN22 allelic variant: Implications in the disease pathogenesis

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Gianchecchi, Elena ^a   Crinò, Antonino ^a   Giorda, Ezio ^a   Luciano, Rosa ^a   Perri, Valentina ^a   Russo, Anna Lo ^a   Cappa, Marco ^a   Rosado, M Manuela ^a   Fierabracci, Alessandra ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; IMMUNOGLOBULIN M; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; TOLL LIKE RECEPTOR 9; PTPN22 PROTEIN, HUMAN; TLR9 PROTEIN, HUMAN;

ADAPTIVE IMMUNITY; ADOLESCENT; ADULT; ALLELE; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CELL COMPOSITION; CELLULAR IMMUNITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DIABETOGENESIS; DISEASE ASSOCIATION; DISEASE DURATION; DNA METHYLATION; FEMALE; GASTRITIS; GENE FUNCTION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; HETEROZYGOTE; HOMEOSTASIS; HUMAN; HUMAN CELL; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MEMORY CELL; ONSET AGE; PERIPHERAL LYMPHOCYTE; PHENOTYPE; PLASMA CELL; PRE B LYMPHOCYTE; PRESCHOOL CHILD; PTPN22 GENE; SCHOOL CHILD; CELL DIFFERENTIATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; PANCREAS ISLET BETA CELL; PATHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE;

ADOLESCENT; ADULT; ALLELES; B-LYMPHOCYTES; CELL DIFFERENTIATION; CHILD; CPG ISLANDS; DIABETES MELLITUS, TYPE 1; DNA, BACTERIAL; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HOMEOSTASIS; HUMANS; INSULIN-SECRETING CELLS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 22; T-LYMPHOCYTES; TOLL-LIKE RECEPTOR 9;

EID: 84908180955     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110755     Document Type: Article

References (49)

1. Gianchecchi E, Palombi M, Fierabracci A (2013) The putative role of the C1858T polymorphism of protein tyrosine phosphatase PTPN22 gene in autoimmunity. Autoimmun Rev 12: 717-725.
2. Burn GL, Svensson L, Sanchez-Blanco C, Saini M, Cope AP (2011) Why is PTPN22 a good candidate susceptibility gene for autoimmune disease? FEBS Lett 585: 3689-3698.
3. Bottini N, Vang T, Cucca F, Mustelin T (2006) Role of PTPN22 in type 1 diabetes and other autoimmune diseases. Semin Immunol 18: 207-213.
4. Rhee I, Veillette A (2012) Protein tyrosine phosphatases in lymphocyte activation and autoimmunity. Nat Immunol 13: 439-447.
5. Wang S, Dong H, Han J, Ho WT, Fu X, et al. (2010) Identification of a variant form of tyrosine phosphatase LYP. BMC Mol Biol 11: 78.
6. Vang T, Miletic AV, Arimura Y, Tautz L, Rickert RC, et al. (2008) Protein tyrosine phosphatases in autoimmunity. Annu Rev Immunol 26: 29-55.
7. Vang T, Congia M, Macis MD, Musumeci L, Orrú V, et al. (2005) Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat Genet 37: 1317-1319.
8. Tang S, Peng W, Wang C, Tang H, Zhang Q (2012) Association of the PTPN22 gene (+1858C/T, 21123G/C) polymorphisms with type 1 diabetes mellitus: a systematic review and meta-analysis. Diabetes Res Clin Pract 97: 446-452.
9. Velaga MR, Wilson V, Jennings CE, Owen CJ, Herington S, et al. (2004) The codon 620 tryptophan allele of the lymphoid tyrosine phosphatase (LYP) gene is a major determinant of Graves' disease. J Clin Endocrinol Metab 89: 5862-5865.
10. Dittmar M, Kahaly GJ (2010) Genetics of the autoimmune polyglandular syndrome type 3 variant. Thyroid 20: 737-743.
11. Vandiedonck C, Capdevielle C, Giraud M, Krumeich S, Jais J-P, et al. (2006) Association of the PTPN22∗R620W polymorphism with autoimmune myasthenia gravis. Ann Neurol 59: 404-407.
12. Orozco G, Sánchez E, González-Gay MA, López-Nevot MA, Torres B, et al. (2005) Association of a functional single-nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheum 52: 219-224.
13. Wu H, Cantor RM, Graham DSC, Lingren CM, Farwell L, et al. (2005) Association analysis of the R620W polymorphism of protein tyrosine phosphatase PTPN22 in systemic lupus erythematosus families: increased T allele frequency in systemic lupus erythematosus patients with autoimmune thyroid disease. Arthritis Rheum 52: 2396-2402.
14. Jagiello P, Aries P, Arning L, Wagenleiter SEN, Csernok E, et al. (2005) The PTPN22 620W allele is a risk factor for Wegener's granulomatosis. Arthritis Rheum 52: 4039-4043.
15. Rieck M, Arechiga A, Onengut-Gumuscu S, Greenbaum C, Concannon P, et al. (2007) Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes. J Immunol 179: 4704-4710.
16. Aarnisalo J, Treszl A, Svec P, Marttila J, Oling V, et al. (2008) Reduced CD4+T cell activation in children with type 1 diabetes carrying the PTPN22/Lyp 620Trp variant. J Autoimmun 31: 13-21.
17. Sakaguchi N, Takahashi T, Hata H, Nomura T, Tagami T, et al. (2003) Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature 426: 454-460.
18. Maine CJ, Hamilton-Williams EE, Cheung J, Stanford SM, Bottini N, et al. (2012) PTPN22 alters the development of regulatory T cells in the thymus. J Immunol 188: 5267-5275.
19. Arechiga AF, Habib T, He Y, Zhang X, Zhang Z-Y, et al. (2009) Cutting edge: the PTPN22 allelic variant associated with autoimmunity impairs B cell signaling. J Immunol 182: 3343-3347.
20. Habib T, Funk A, Rieck M, Brahmandam A, Dai X, et al. (2012) Altered B cell homeostasis is associated with type I diabetes and carriers of the PTPN22 allelic variant. J Immunol 188: 487-496.
21. Menard L, Saadoun D, Isnardi I, Ng Y-S, Meyers G, et al. (2011) The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans. J Clin Invest 121: 3635-3644.
22. Michou L, Lasbleiz S, Rat A-C, Migliorini P, Balsa A, et al. (2007) Linkage proof for PTPN22, a rheumatoid arthritis susceptibility gene and a human autoimmunity gene. Proc Natl Acad Sci U S A 104: 1649-1654.
23. Wang Y, Shaked I, Stanford SM, Zhou W, Curtsinger JM, et al. (2013) The autoimmunity-associated gene PTPN22 potentiates toll-like receptor-driven, type 1 interferon-dependent immunity. Immunity 39: 111-122.
24. Ivashkiv LB, Donlin LT (2013) Regulation of type I interferon responses. Nat Rev Immunol 14: 36-49.
25. Fierabracci A (2011) Peptide immunotherapies in Type 1 diabetes: lessons from animal models. Curr Med Chem 18: 577-586.
26. Serreze D V, Fleming SA, Chapman HD, Richard SD, Leiter EH, et al. (1998) B lymphocytes are critical antigen-presenting cells for the initiation of T cellmediated autoimmune diabetes in nonobese diabetic mice. J Immunol 161: 3912-3918.
27. Meffre E, Wardemann H (2008) B-cell tolerance checkpoints in health and autoimmunity. Curr Opin Immunol 20: 632-638.
28. Hu C, Rodriguez-Pinto D, Du W, Ahuja A, Henegariu O, et al. (2007) Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest 117: 3857-3867.
29. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, et al. (2009) Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 361: 2143-2152.
30. Herold KC, Pescovitz MD, McGee P, Krause-Steinrauf H, Spain LM, et al. (2011) Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes. J Immunol 187: 1998-2005.
31. Wen L, Peng J, Li Z, Wong FS (2004) The effect of innate immunity on autoimmune diabetes and the expression of Toll-like receptors on pancreatic islets. J Immunol 172: 3173-3180.
32. Tai N, Wong FS, Wen L (2013) TLR9 deficiency promotes CD73 expression in T cells and diabetes protection in nonobese diabetic mice. J Immunol 191: 2926-2937.
33. Wong FS, Hu C, Zhang L, Du W, Alexopoulou L, et al. (2008) The role of Tolllike receptors 3 and 9 in the development of autoimmune diabetes in NOD mice. Ann N Y Acad Sci 1150: 146-148.
34. Diana J, Moura IC, Vaugier C, Gestin A, Tissandie E, et al. (2013) Secretory IgA induces tolerogenic dendritic cells through SIGNR1 dampening autoimmunity in mice. J Immunol 191: 2335-2343.
35. Capolunghi F, Cascioli S, Giorda E, Rosado MM, Plebani A, et al. (2008) CpG drives human transitional B cells to terminal differentiation and production of natural antibodies. J Immunol 180: 800-808.
36. Carsetti R, Rosado MM, Wardmann H. (2004). Peripheral development of B cells in mouse and man. Immunol Rev.197: 179-911.
37. Bottini N, Musumeci L, Alonso A, Rahmouni S, Nika K, et al. (2004) A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet 36: 337-338.
38. Shlomchik MJ (2008) Sites and stages of autoreactive B cell activation and regulation. Immunity 28: 18-28.
39. Rahman A, Isenberg DA (2008) Systemic lupus erythematosus. N Engl J Med 358: 929-939.
40. Capolunghi F, Rosado MM, Cascioli S, Girolami E, Bordasco S, et al. (2010) Pharmacological inhibition of TLR9 activation blocks autoantibody production in human B cells from SLE patients. Rheumatology (Oxford) 49: 2281-2289.
41. Fierabracci A (2009) Unravelling autoimmune pathogenesis by screening random peptide libraries with human sera. Immunol Lett 124: 35-43.
42. Anderson MS, Bluestone JA (2005) The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 23: 447-485.
43. Casali P, Schettino EW (1996) Structure and function of natural antibodies. Curr Top Microbiol Immunol 210: 167-179.
44. Capolunghi F, Rosado MM, Sinibaldi M, Aranburu A, Carsetti R (2013) Why do we need IgM memory B cells? Immunol Lett 152: 114-120.
45. Côrte-Real J, Duarte N, Tavares L, Penha-Gonçalves C (2012) Innate stimulation of B1a cells enhances the autoreactive IgM repertoire in the NOD mouse: implications for type 1 diabetes. Diabetologia 55: 1761-1772.
46. Chatenoud L, Bach JF (1990) Monoclonal antibodies to CD3 as immunosuppressants. Semin Immunol 2: 437-447.
47. Yu L, Herold K, Krause-Steinrauf H, McGee PL, Bundy B, et al. (2011) Rituximab selectively suppresses specific islet antibodies. Diabetes 60: 2560-2565.
48. Gallagher MP, Goland RS, Greenbaum CJ (2011) Making progress: preserving beta cells in type 1 diabetes. Ann N Y Acad Sci 1243: 119-134.
49. Pescovitz MD, Greenbaum CJ, Bundy B, Becker DJ, Gitelman SE, et al. (2013) B-Lymphocyte Depletion with Rituximab and Beta-Cell Function: Two-Year Results. Diabetes Care 37: 453-459.